Long-term treatment of angina pectoris.
Cytoprotective Anti-ischaemic
Trimetazidine Dihydrochloride is the first 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary patients. Trimetazidine Dihydrochloride inhibits fatty acid pathway by inhibiting 3-keto acyl CoA thiolase enzyme and transfers oxygen to glucose pathway. Since glucose pathway is more efficient in producing energy, the same oxygen produces more energy and makes the heart more active. Moreover, the aerobic oxidation of glucose stops production of lactic acid, which prevents angina pectoris.
1 tablet at mealtimes in the morning & evening.
No drug interaction so far has been reported. In particular, no interaction has been reported with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis preparation.
Severe depression, severe renal failure (creatinine clearance <15 ml/min), as a precaution in the absence of currently available studies.
Rare cases of gastrointestinal disorders.
Pregnancy: Studies in animals have not demonstrated a teratogenic Effect. However, in the absence of clinical data & for safety reasons, prescription should be avoided during pregnancy. Breastfeeding: In the absence of data, breastfeeding is not recommended during treatment.
Keep in a dry place away from light and heat. Keep out of the reach of children.
.png&w=384&q=75)